Atomwise, Hansoh Pharma Enter Into Up-to-$1.5B AI-Based Drug Discovery Partnership

GEN | September 12, 2019

Atomwise and Jiangsu Hansoh Pharmaceutical Group—the Chinese company behind this year’s largest biopharma initial public offering (IPO)—said today they have launched an up-to-$1.5 billion collaboration to design and discover potential drug candidates for up to 11 undisclosed target proteins in cancer and “multiple” other therapeutic areas. The collaboration is intended to combine Atomwise’s AI technology, medicinal chemistry, and protein structure expertise with Hansoh Pharma’s fully integrated R&D, manufacturing, and commercial capabilities, with the aim of accelerating and improving drug discovery and clinical development, Atomwise said. Atomwise uses AI for its structure-based, drug design technology, which is based on convolutional neural networks along the lines of those that recognize faces in a crowd or enable self-driving cars. Atomwise’s AI technology is designed to enable scientists to predict how well a small molecule will bind to a target protein of interest, as well as remove sole reliance on empirical screening. The company says its AtomNet platform is designed to screen billions of compounds, and has demonstrated success using homology-modeled proteins.

Spotlight

In the pharmaceutical environment, and especially in the research and development field, the quality of the medicine is a critical step as it is facing challenges with increased? demand from the regulatory affairs to improve the quality of a pharmaceutical drug product. In order to ensure its proper effect on the patient health, a product has to be manufactured with the appropriate quality.

Spotlight

In the pharmaceutical environment, and especially in the research and development field, the quality of the medicine is a critical step as it is facing challenges with increased? demand from the regulatory affairs to improve the quality of a pharmaceutical drug product. In order to ensure its proper effect on the patient health, a product has to be manufactured with the appropriate quality.

Related News

BUSINESS INSIGHTS

ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement

ERS Genomics | July 27, 2022

ERS Genomics Limited is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD. This is a non-exclusive licensing agreement granting Lepton access to the ERS CRISPR/Cas9 patent portfolio for certain applications. ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Over 90 patents are held in over eighty countries. Lepton Pharmaceutical LTD is a biotechnology company developing a proprietary, breakthrough technology to substantially improve adaptive cell-mediated immune response. "We are very pleased to establish this relationship and license agreement with ERS Genomics. It will greatly assist us to develop our innovative Castling technology to significantly improve immune cells efficiency and longevity to fight cancer." Dr. Daniel Zurr, CEO of Lepton Eric Rhodes, CEO at ERS Genomics added: "Lepton's Castling technology has great potential to impact the field of immunotherapies and we are pleased to help enable Lepton in pursuing this exciting approach." The Castling technology is a proprietary, miRNA-based general technology platform, essentially consisting of the manipulation of miRNA expression to achieve enhanced efficacy and longevity (reduced exhaustion) of cell-based therapies. miRNAs are noncoding RNAs that each affects the expression of hundreds of coding genes. The Castling technology allows, in a single gene editing event in the immune cell (either allogeneic or autologous), to impact the expression of a multitude of genes in the immune cells, once such miRNAs penetrate the microenvironment of cancer cells. This technology aims to revolutionize the immune cell cancer therapy field. About ERS Genomics ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; companion animal and livestock health; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. About Lepton Pharmaceuticals Lepton Pharmaceuticals LTD. is based in Israel. Lepton focuses on subtle and precise silencing of coding RNA expression by small non-coding RNA molecules, working via the DROSHA/DICER/RISC pathways, small interfering RNA and microRNA (miRNA), to develop products and services to, ultimately, improve therapies for underserved diseases and improve and change patients' lives.

Read More

PHARMACY MARKET

GluCare.Health Partners with Novo Nordisk for Innovative Weight Management Patient Program

Glucare.Health and NovoNordisk: | June 09, 2022

GluCare.Health, one of the Middle East's leading health tech startups, has partnered with global pharmaceutical company Novo Nordisk, market leader in Diabetes & Obesity, to introduce a blueprint for the future of healthcare. The partnership will see a 150-patient weight management pilot program that will combine new digital bio-markers, using wearable technology and devices for continuous data monitoring, with existing therapeutics. It introduces the Middle East's first value-based reimbursement model, and will be the first relationship of its kind for Novo Nordisk globally. This innovative partnership will put accountability for outcomes vs. costs on the provider, rather than on the insurers or patients. The 6-month program, which begins in September, is open to people with obesity who meet certain criteria. Patients will receive an unparalleled level of in-patient and data-driven remote care, with a multidisciplinary clinic team having continuous access to all patient data through an intelligent analytical platform. If patients do not lose at least 10% of their body weight by the end of the program, GluCare.Health and Novo Nordisk will cover all or a portion of the cost under the value-based reimbursement pilot. GluCare.Health is also committed to transparency when it comes to reporting results of the program. With one in three adults affected by obesity in the UAE[1], GluCare.Health's Co-Founder and Managing Director, Dr. Ihsan AlMarzooqi, says that the blueprint for care has the potential to not only save many lives but the UAE economy billions of dollars in costs and lost productivity. "When patients with chronic conditions are not supported properly, it can have a devastating impact on those individuals and their families. Additionally, the cost of treating the health consequences of obesity to the UAE economy alone is approximately $3.6 billion annually[2]. Traditional models of care remain woefully limited when it comes to outcomes. This partnership allows us to embed Novo Nordisk's advanced therapeutics into a companion platform like GluCare.Health, which enhances its efficacy dramatically." About Glucare.Health The first hybrid Digital Therapeutics (DTx)+Human vertically integrated diabetes platform of its kind in the world, GluCare.Health is reinventing metabolic care and transforming lives. Conceptualized in the UAE and opening the doors to its state-of-the-art 10,000 sq foot Dubai clinic in September 2020, it is the world's first healthcare provider to empower both clinicians and patients through Remote Continuous Data Monitoring as part of its standard model of care, an innovative and highly personalized 'continuous healthcare' approach that provides a comprehensive and real-time view of patients. As part of its unique model, GluCare is also an early adopter of - and the region's first clinic to use - Digital Therapeutics (DTx), combining it with wearable and smart technology, data analytics, unique in-clinic workflows, and a caring and connected expert care team. Applying technology as a humanizing force, GluCare.Health's team partners with patients and their families, giving them the tools, knowledge, and continuous support to live longer, healthier, and more fulfilling lives. About NovoNordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. For more information, visit Novo Nordisk UAE.

Read More

BUSINESS INSIGHTS

ILC Dover Becomes a Provider of Ascent / Entry Spacesuits for Boeing's Starliner

ILC Dover | May 27, 2022

ILC Dover, the leading provider of spacesuits since the Apollo era, announced that it was selected to be one of two providers of Boeing's Ascent/Entry Suit for the company's Commercial Crew Program and has developed a bespoke AES spacesuit for CST-100 Starliner crews. "We are proud to utilize our expertise to create a new AES for the Starliner spacecraft. Having worked with the Boeing team on the Starliner's landing airbags, which provide a safe, cushioned arrival to Earth from space, we understood the importance of delivering another quality product for this program." Patty Stoll, President of Space Systems and Engineered Solutions at ILC Dover The Boeing AES is based off ILC Dover's commercial Launch, Entry, and Abort suit, SOL™. ILC Dover worked with Boeing to tailor SOL for the Starliner spacecraft to provide protection for astronauts during the most critical phases of spaceflight, including launch, docking, re-entry and landing. With over 50 years of spacesuit experience, the AES suit was designed to provide maximum mobility to operate, enter and exit the spacecraft, as well as provide protection for astronauts in case of an emergency. "Our success is measured by those we've helped return to Earth safely for over 50 years of space travel and we will continue to provide spacesuits and soft solutions that will keep astronauts safe in the harsh environment of space," said Stoll. Working with ILC Dover's in-house fashion designer, the cover layer of the spacesuit was designed with a unique look for Starliner crew members. A replica of the Starliner AES will be on display on Florida's Space Coast at the Kennedy Space Center Visitor Complex's new attraction called Gateway: The Deep Space Launch Complex. ILC Dover and Boeing worked with Adam Savage, television personality and longtime special effects designer and fabricator, to create the replica. About ILC Dover ILC Dover is a world-leader in the innovative design and production of solutions for biopharmaceutical, pharmaceutical, medical device markets as well as a leading supplier for the space industries. Our customers will attest to our relentless dedication to high value products, advanced technology, and responsive service, as our visionary solutions have improved efficiency while safeguarding people, product, and infrastructure in hazardous conditions through flexible protective solutions since 1947.

Read More